All Articles

The food giant's $250M bond repurchase offer was nearly doubly oversubscribed, a strong market endorsement of its financial health and strategic debt management.

IVY Rx unveils its 2026 compounded GLP-1 program with clear pricing, but operates in a market facing intense FDA warnings and regulatory uncertainty.

The market for at-home NAD+ therapy is booming, but as telehealth offers new convenience, it faces a wave of regulatory and safety questions.

Replimune halts a promising cancer therapy and cuts jobs after a stunning FDA rejection, citing a 'failed' system and inconsistent regulatory process.

Allogene Therapeutics faces a make-or-break moment as it prepares to unveil crucial trial data for its 'off-the-shelf' cancer therapy, cema-cel.

Diamondback Energy is buying back nearly $1 billion in long-term debt. What does this strategic financial move reveal about its future and the energy sector?

Investors watch Gibson Energy closely as it prepares for its Q1 results amid mixed performance, strategic acquisitions, and a changing energy landscape.

Amid a complex economy, DPC Dash is rapidly expanding, breaking global sales records and winning millions with a unique digital and cultural strategy.

Stephan Crétier, who turned a $25k loan into a $14B security empire, will keynote at SWGSB, offering bankers crucial lessons in risk and resilience.

MOVA AtomForm's new Palette 300 uses 12 nozzles and AI to promise waste-free, high-speed multi-color printing. But can it deliver on its bold claims?

After a devastating crash left them with traumatic brain injuries, a NM couple secured a major settlement. Their story reveals the true cost of drunk driving.

Despite global jitters, luxury property in San Miguel de Allende and Querétaro is thriving. Discover why buyers are flocking to these Mexican hotspots.

Less than a year after its acquisition, Khoros launches Iris AI, an 'AI-native' platform aiming to unify customer engagement and unseat market leaders.

A jury found Abbott's Similac caused a fatal gut disease in premature infants, igniting a legal firestorm over what the formula giant knew and when.

A Chicago jury found Abbott liable for infants' injuries from Similac, adding to a wave of lawsuits over the deadly intestinal disease NEC.

Gensler's Andy Cohen joins the REIT's board, signaling a strategic shift toward design-led development in LA and Honolulu's premium real estate markets.

Novarad showcases its FDA-cleared VisAR system, an AR platform promising sub-millimeter accuracy and faster workflows for interventional radiology.

With a $2.135M financing round complete, Golden Shield Resources turns its focus to permitting its promising Marudi Mountain gold project in Guyana.

The junior energy firm navigates a critical leadership transition following the death of Gordon Bowerman, a pivotal figure in its strategy and history.

After sweeping awards, 'The Ebony Canal' takes its powerful message on Black maternal health from Hollywood to a global stage, aiming for systemic change.